Literature DB >> 22544329

The DNA damage checkpoint protein ATM promotes hepatocellular apoptosis and fibrosis in a mouse model of non-alcoholic fatty liver disease.

Erin K Daugherity1, Gabriel Balmus, Ahmed Al Saei, Elizabeth S Moore, Delbert Abi Abdallah, Arlin B Rogers, Robert S Weiss, Kirk J Maurer.   

Abstract

Steatoapoptosis is a hallmark of non-alcoholic fatty liver disease (NAFLD) and is an important factor in liver disease progression. We hypothesized that increased reactive oxygen species resulting from excess dietary fat contribute to liver disease by causing DNA damage and apoptotic cell death, and tested this by investigating the effects of feeding mice high fat or standard diets for 8 weeks. High fat diet feeding resulted in increased hepatic H 2O 2, superoxide production, and expression of oxidative stress response genes, confirming that the high fat diet induced hepatic oxidative stress. High fat diet feeding also increased hepatic steatosis, hepatitis and DNA damage as exemplified by an increase in the percentage of 8-hydroxyguanosine (8-OHG) positive hepatocytes in high fat diet fed mice. Consistent with reports that the DNA damage checkpoint kinase Ataxia Telangiectasia Mutated (ATM) is activated by oxidative stress, ATM phosphorylation was induced in the livers of wild type mice following high fat diet feeding. We therefore examined the effects of high fat diet feeding in Atm-deficient mice. The prevalence of apoptosis and expression of the pro-apoptotic factor PUMA were significantly reduced in Atm-deficient mice fed the high fat diet when compared with wild type controls. Furthermore, high fat diet fed Atm (-/-) mice had significantly less hepatic fibrosis than Atm (+/+) or Atm (+/-) mice fed the same diet. Together, these data demonstrate a prominent role for the ATM pathway in the response to hepatic fat accumulation and link ATM activation to fatty liver-induced steatoapoptosis and fibrosis, key features of NAFLD progression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22544329      PMCID: PMC3359121          DOI: 10.4161/cc.20259

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  52 in total

1.  Steatohepatitis and apoptosis: therapeutic implications.

Authors:  Ariel Feldstein; Gregory J Gores
Journal:  Am J Gastroenterol       Date:  2004-09       Impact factor: 10.864

2.  CHOP and AP-1 cooperatively mediate PUMA expression during lipoapoptosis.

Authors:  Sophie C Cazanave; Nafisa A Elmi; Yuko Akazawa; Steven F Bronk; Justin L Mott; Gregory J Gores
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-04-29       Impact factor: 4.052

3.  Impaired hepatocyte survival and liver regeneration in Atm-deficient mice.

Authors:  Shu Lu; Kate C Shen; Yaolin Wang; S C Brooks; Y Alan Wang
Journal:  Hum Mol Genet       Date:  2005-09-02       Impact factor: 6.150

Review 4.  Current therapeutic strategies in non-alcoholic fatty liver disease.

Authors:  J K Dowman; M J Armstrong; J W Tomlinson; P N Newsome
Journal:  Diabetes Obes Metab       Date:  2011-08       Impact factor: 6.577

Review 5.  Apoptosis in alcoholic and nonalcoholic steatohepatitis.

Authors:  Ariel E Feldstein; Gregory J Gores
Journal:  Front Biosci       Date:  2005-09-01

6.  Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial.

Authors:  Temitope Foster; Matthew J Budoff; Sammy Saab; Naser Ahmadi; Craig Gordon; Alan D Guerci
Journal:  Am J Gastroenterol       Date:  2010-09-14       Impact factor: 10.864

Review 7.  The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology.

Authors:  Stephen Caldwell; Sang H Park
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

8.  Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma.

Authors:  Y Xu; T Ashley; E E Brainerd; R T Bronson; M S Meyn; D Baltimore
Journal:  Genes Dev       Date:  1996-10-01       Impact factor: 11.361

9.  Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo.

Authors:  Shan-Shan Zhan; Joy X Jiang; Jian Wu; Charles Halsted; Scott L Friedman; Mark A Zern; Natalie J Torok
Journal:  Hepatology       Date:  2006-03       Impact factor: 17.425

10.  T-cell function is critical for murine cholesterol gallstone formation.

Authors:  Kirk J Maurer; Varada P Rao; Zhongming Ge; Arlin B Rogers; Trisha J Oura; Martin C Carey; James G Fox
Journal:  Gastroenterology       Date:  2007-10       Impact factor: 22.682

View more
  30 in total

1.  The p53 Codon 72 Polymorphism Modifies the Cellular Response to Inflammatory Challenge in the Liver.

Authors:  Julia I-Ju Leu; Maureen E Murphy; Donna L George
Journal:  J Liver       Date:  2013

2.  PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells.

Authors:  Jane L Roberts; Laurence Booth; Adam Conley; Nichola Cruickshanks; Mark Malkin; Rakesh C Kukreja; Steven Grant; Andrew Poklepovic; Paul Dent
Journal:  Cancer Biol Ther       Date:  2014-03-20       Impact factor: 4.742

Review 3.  Hagen-Poiseuille's law: The link between cirrhosis, liver stiffness, portal hypertension and hepatic decompensation.

Authors:  Gerond Lake-Bakaar; Muneeb Ahmed; Amy Evenson; Alan Bonder; Salomao Faintuch; Vinay Sundaram
Journal:  World J Hepatol       Date:  2015-01-27

Review 4.  DNA damage response and sphingolipid signaling in liver diseases.

Authors:  Masayuki Nagahashi; Yasunobu Matsuda; Kazuki Moro; Junko Tsuchida; Daiki Soma; Yuki Hirose; Takashi Kobayashi; Shin-Ichi Kosugi; Kazuaki Takabe; Masaaki Komatsu; Toshifumi Wakai
Journal:  Surg Today       Date:  2015-10-29       Impact factor: 2.549

Review 5.  Frequently mutated genes/pathways and genomic instability as prevention targets in liver cancer.

Authors:  Chinthalapally V Rao; Adam S Asch; Hiroshi Y Yamada
Journal:  Carcinogenesis       Date:  2016-11-12       Impact factor: 4.944

6.  The role of iNOS in cholesterol-induced liver fibrosis.

Authors:  Sarit Anavi; Michal Eisenberg-Bord; Michal Hahn-Obercyger; Olga Genin; Mark Pines; Oren Tirosh
Journal:  Lab Invest       Date:  2015-06-22       Impact factor: 5.662

7.  Sex-specific hepatic lipid and bile acid metabolism alterations in Fancd2-deficient mice following dietary challenge.

Authors:  Elizabeth S Moore; Erin K Daugherity; David I Karambizi; Bethany P Cummings; Erica Behling-Kelly; Deanna M W Schaefer; Teresa L Southard; Joseph W McFadden; Robert S Weiss
Journal:  J Biol Chem       Date:  2019-08-21       Impact factor: 5.157

Review 8.  Management of Hepatocellular Carcinoma in Cirrhotic Patients with Portal Hypertension: Relevance of Hagen-Poiseuille's Law.

Authors:  Gerond Lake-Bakaar; Muneeb Ahmed; Amy Evenson; Alan Bonder; Salomao Faintuch; Vinay Sundaram
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

9.  Mildly compromised tetrahydrobiopterin cofactor biosynthesis due to Pts variants leads to unusual body fat distribution and abdominal obesity in mice.

Authors:  Germaine Korner; Tanja Scherer; Dea Adamsen; Alexander Rebuffat; Mark Crabtree; Anahita Rassi; Rossana Scavelli; Daigo Homma; Birgit Ledermann; Daniel Konrad; Hiroshi Ichinose; Christian Wolfrum; Marion Horsch; Birgit Rathkolb; Martin Klingenspor; Johannes Beckers; Eckhard Wolf; Valérie Gailus-Durner; Helmut Fuchs; Martin Hrabě de Angelis; Nenad Blau; Jan Rozman; Beat Thöny
Journal:  J Inherit Metab Dis       Date:  2016-02-01       Impact factor: 4.982

Review 10.  From NASH to HCC: current concepts and future challenges.

Authors:  Quentin M Anstee; Helen L Reeves; Elena Kotsiliti; Olivier Govaere; Mathias Heikenwalder
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-07       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.